Is NCT07216235 recruiting in Houston, TX?

Yes, NCT07216235 is currently recruiting participants at its Houston, TX location. This primary biliary cholangitis clinical trial is actively enrolling qualified participants.

How do I join the primary biliary cholangitis clinical trial in Houston?

To join this clinical trial in Houston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Houston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Primary Biliary Cholangitis Clinical Trial in Houston, TX

Who Can Participate

Inclusion Criteria

Each participant must meet all of the following criteria to be enrolled in this study:

Is capable of understanding the written informed consent, provides signed and witnessed written informed consent, and agrees to comply with protocol requirements

Is an adult male or female, must be ≥18 years of age at the time of signing informed consent

Is receiving ursodeoxycholic acid (UDCA) for ≥12 months with a stable dose for ≥6 months prior to screening,and expected to remain on a stable dose during the study period OR Is unable to tolerate UDCA and did not receive UDCA in the past 3 months prior to screening

Has a history of confirmed PBC diagnosis, as demonstrated by the presence of ≥2 of the following 3 diagnostic factors: i. A history of elevated ALP levels for ≥6 months prior to screening ii. Positive antimitochondrial antibodies (AMA) titer OR if AMA is negative, then positive PBC-specific antibodies iii. Liver biopsy consistent with PBC diagnosis

Has documented evidence of cirrhosis and has ALP \>ULN and TB ≤5 × ULN

Exclusion Criteria

Participants meeting any of the following criteria will be excluded from the study:

Has consumption of 2 standard alcohol drinks per day (or 14 alcohol drinks per week) if male and 1 standard alcohol drink per day (or 7 alcohol drinks per week) if female for ≥3 consecutive months (12 consecutive weeks) within 5 years prior to screening

Has known CPT B (having a score of ≥7) or CPT C (having a score of ≥10) cirrhosis classification at screening

Has a Model for End-Stage Liver Disease (MELD)-Na score of ≥12 at screening

Has a history or presence of any of the following other concomitant liver diseases at screening: i. Chronic hepatitis B or C virus (HBV, HCV) infection. (Note: If a participant has been treated for the HCV infection and has been cured for a duration of \>2 years prior to screening, they can be enrolled in the study. Participants who have seroconverted (hepatitis B surface antigen-negative and hepatitis B surface antibody-positive) may be included in this study. ii. Primary sclerosing cholangitis iii. Alcohol-associated liver diseases iv. Autoimmune hepatitis (AIH)-PBC overlap syndrome v. Hemochromatosis vi. Metabolic dysfunction-associated steatohepatitis on historical biopsy vii. α-1 antitrypsin deficiency

Has a history or presence of clinically significant hepatic decompensation, including the following: i. Liver transplantation or currently placed on a liver transplant list ii. Complications of cirrhosis iii. Hepatorenal syndrome (Type I or II) iv. Known or suspected hepatocellular carcinoma or other hepatobiliary malignancies

Use of the following medications (within 12 weeks prior to screening until the randomization \[Day 1\] visit): thiazolidinediones, fibrates, OCA, methotrexate, budesonide, and other systemic corticosteroids (equivalent to prednisone dose \>10 mg); potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid, isoniazid, and nitrofurantoin); any other newly approved treatments for PBC (eg, elafibranor, seladelpar)

Has elevated baseline ALT, AST, or ALP values; ALT, AST, or ALP values increasing by \>50% on Visit 2 compared to Visit 1

Has any of the following laboratory values: i. TB \>5 × ULN ii. Platelets \<50 × 10\^9/L iii. Albumin \<2.8 g/dL iv. ALP \>10 × ULN v. Estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73m\^2 vi. ALT or AST \>5 × ULN vii. International normalized ratio (INR) \>1.7 in the absence of anticoagulant therapy viii. CPK \> 2x ULN

Has participated in another interventional clinical study and received any other investigational medication or medical device within 30 days or 5 half lives, whichever is longer, prior to screening

Has a history of malignancy in the past 5 years and/or active neoplasm, which may diminish life expectancy (except resolved superficial nonmelanoma skin cancer, carcinomas in situ, or other stable, relatively benign conditions prior to screening)

Has a known allergy, hypersensitivity, or intolerance to saroglitazar or any of the formulation ingredients

Pregnancy-related exclusions, including the following: i. If a female, who is pregnant (including a positive pregnancy test at screening), breastfeeding, intends to become pregnant, or is a woman of childbearing potential and not agreeing to use adequate contraceptive methods for the duration of the study and for at least 1 month after receiving the last dose of the IP ii. Male participants with WOCBP partners and female participants must avoid pregnancy either by true abstinence or the use of acceptable, effective contraceptive measures for the duration of the study and for at least 1 month after receiving the last dose of the IP

Has a history or other evidence of severe illness or any other conditions, including cardiovascular, endocrine, hematological, gastrointestinal, neurological, or psychiatric disease, that, in the opinion of the investigator, would make the participant unsuitable for the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT07216235) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Primary Biliary Cholangitis Treatment Options in Houston, TX

If you're searching for primary biliary cholangitis treatment options in Houston, TX, this clinical trial (NCT07216235) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced primary biliary cholangitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all primary biliary cholangitis clinical trials near you to find additional studies recruiting in your area.

Primary Biliary Cholangitis Clinical Trial in Houston, TX

Expert Care in Houston

IRB Approved

No-Cost Care

Apply for This Houston Location

Why Participate?

Simple Process

About This Primary Biliary Cholangitis Study in Houston